Cite
HARVARD Citation
Fradet, Y. et al. (2019). Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Annals of oncology. pp. 970-976. [Online].